KRAS and neoplasm: Niclosamide examination of tumor growth associated pathways and MEK1/2-ERK1/2 signaling associated molecules revealed inactivation of MSK1, MEK1/2, and ERK1/2 as well as reduction of K-ras in Niclosamide-treated cells (Figure 1E).